<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289639</url>
  </required_header>
  <id_info>
    <org_study_id>CDA-2-044-08S-2</org_study_id>
    <nct_id>NCT01289639</nct_id>
  </id_info>
  <brief_title>Insulin Resistance in Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>Insulin Resistance in Non-alcoholic Fatty Liver Disease (Protocol Drug Change From Project Career Development Award (CDA)-2-044-08S)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to investigate the relationship between insulin resistance and
      non-alcoholic fatty liver disease (NAFLD) and to investigate potential mechanisms underlying
      insulin resistance in NAFLD by determining associations between hepatic and peripheral
      insulin sensitivity, hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose
      metabolism, beta-cell function and body fat distribution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NAFLD and nonalcoholic steatohepatitis (NASH) are common liver disorders that are strongly
      associated with obesity, type 2 diabetes and dyslipidemia. The underlying pathophysiology of
      fatty infiltration of the liver is thought to be related to insulin resistance, which is an
      almost universal finding in patients with NAFLD. It is also possible that fat infiltration
      and inflammation in the liver may impair insulin sensitivity, either locally in the liver, or
      peripherally via the actions of inflammatory cytokines. We hypothesize that insulin
      resistance is a major causal factor leading to fat deposition in the liver and NAFLD, and
      thus interventions aimed at improving insulin sensitivity will result in a reduction of
      hepatic inflammation and steatosis.

      Specific Aim 1: To determine in a cross-sectional study whether NAFLD is associated with
      altered peripheral and hepatic insulin sensitivity and to study their relationships with
      hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, beta-cell
      function and body fat distribution. Specific Aim 2: To determine in a 6 month
      placebo-controlled double-blinded treatment study if treatment with pioglitazone, an insulin
      sensitizer, or fenofibrate, a triglyceride lowering agent, will improve both hepatic as well
      as peripheral insulin sensitivity and thereby improve hepatic steatosis and inflammation in
      subjects with NAFLD.

      The results of the proposed study will have important implications for our understanding of
      the mechanisms underlying insulin resistance and abnormalities in lipid and glucose
      metabolism in subjects with NAFLD and for the design of future studies aimed at the
      prevention and treatment of this condition.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment in intervention study. Baseline data published.
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver/Spleen Ratio Measured as the Ratio in Hounsfield Units Between the Liver and the Spleen on Computed Tomography (CT) Scan</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT) Levels</measure>
    <time_frame>0-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver/Spleen Ratio Measure by the Density Ratio in Hounsfield Units Between the Liver and the Spleen by CT</measure>
    <time_frame>0-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peripheral Insulin Sensitivity</measure>
    <time_frame>0-6 months</time_frame>
    <description>Change in the rate of glucose disposal (Rd) during the low dose clamp. During a clamp procedure, insulin is infused at a dose based on body size and a glucose solution is infused and the rate adjusted every 5 minutes based on a blood glucose reading to maintain the blood glucose stable at 90 mg/dl (normal level). Using glucose isotopes and the rate of the glucose infusion, we are then able to calculate how much glucose the liver is producing and how much glucose is being taken up into tissues. This provides a measure of insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intra-abdominal Fat Area by CT Scan</measure>
    <time_frame>0-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hepatic Insulin Sensitivity</measure>
    <time_frame>0-6 months</time_frame>
    <description>Hepatic insulin sensitivity was determined using stable glucose isotope measurements during the low dose hyperinsulinemic euglycemic clamp to determine the rate of endogenous glucose production in the fasting state and in response to a low dose glucose infusion. The ability of insulin to suppress glucose, which is mainly produced by the liver, thus provides a measure of hepatic insulin sensitivity and is expressed as a percentage of the basal state. Change in the ability of low dose insulin to suppress endogenous glucose production during a labeled hyperinsulinemic euglycemic clamp.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo 1 po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>micronized fenofibrate 200 mg 1 po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pioglitazone 30 mg po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>micronized fenofibrate 200 mg 1 po qd</description>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>micronized fenofibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>pioglitazone 30 mg po qd</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 1 capsule po qd</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Control subjects: nl liver enzymes and no history of liver disease Case subjects: NAFLD on
        liver biopsy within the past 3 years or presumed NAFLD with otherwise unexplained elevated
        alanine aminotransferase (ALT) and fatty liver by computerized tomography (CT) scan or
        ultrasound

          -  Able to comply with taking 1 pill a day for 6 months and follow-up safety visits

        Exclusion Criteria:

          -  Cases: cirrhosis on liver biopsy or by clinical exam or fibrosis score

          -  Causes of liver dysfunction other than NASH

          -  Use of medications associated with hepatic steatosis:

               -  glucocorticoids

               -  estrogens

               -  tamoxifen

               -  amiodarone

               -  accutane

               -  sertraline

          -  Use of medications that cause insulin resistance:

               -  niacin

               -  glucocorticoids

               -  anti-HIV drugs or atypical antipsychotics

          -  Use of lipid-lowering medications except stable dose statin

          -  Use of anti-NASH drugs such as ursodeoxycholic acid, betaine milk thistle

          -  Use of coumadin

          -  Use of nitrates

          -  Significant alcohol consumption: Average &gt;20 grams/day

          -  In subjects with diabetes, a hemoglobin A1c (HbA1c) &gt;7.5% or use of insulin,
             metformin, rosiglitazone or pioglitazone

          -  Liver transaminases: ALT &gt;5x upper limit of normal,

          -  Iron saturation &gt;50%

          -  Creatinine &gt;1.5 mg/dl for men and &gt;1.4 mg/dl for women

          -  Hematocrit &lt;33%

          -  Pregnancy or lactation

          -  Significant weight loss within the past 6 months or since the liver biopsy

          -  History of significant coronary artery disease or congestive heart failure,
             retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina M Utzschneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System, Seattle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Utzschneider KM, Largajolli A, Bertoldo A, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Kahn SE. Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women. J Diabetes Complications. 2014 Mar-Apr;28(2):177-84. doi: 10.1016/j.jdiacomp.2013.11.007. Epub 2013 Nov 26.</citation>
    <PMID>24360972</PMID>
  </results_reference>
  <results_reference>
    <citation>Kratz M, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Callahan HS, Song X, Di C, Utzschneider KM. Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans. Am J Clin Nutr. 2014 Jun;99(6):1385-96. doi: 10.3945/ajcn.113.075457. Epub 2014 Apr 16.</citation>
    <PMID>24740208</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <results_first_submitted>October 1, 2014</results_first_submitted>
  <results_first_submitted_qc>October 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2014</results_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-alcoholic fatty liver disease</keyword>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
        </group>
        <group group_id="P3">
          <title>Arm 3</title>
          <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects recruited with known NAFLD or NASH.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>matching placebo for fenofibrate 1 po qd
matching placebo for pioglitazone 1 po qd</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
        </group>
        <group group_id="B3">
          <title>Arm 3</title>
          <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="7.3"/>
                    <measurement group_id="B2" value="54.17" spread="5.08"/>
                    <measurement group_id="B4" value="51.91" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver/Spleen Ratio Measured as the Ratio in Hounsfield Units Between the Liver and the Spleen on Computed Tomography (CT) Scan</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
          </group>
        </group_list>
        <measure>
          <title>Liver/Spleen Ratio Measured as the Ratio in Hounsfield Units Between the Liver and the Spleen on Computed Tomography (CT) Scan</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".85" spread=".08"/>
                    <measurement group_id="O2" value=".60" spread=".17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT) Levels</title>
        <time_frame>0-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT) Levels</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="12.9"/>
                    <measurement group_id="O2" value="-15.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Liver/Spleen Ratio Measure by the Density Ratio in Hounsfield Units Between the Liver and the Spleen by CT</title>
        <time_frame>0-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Liver/Spleen Ratio Measure by the Density Ratio in Hounsfield Units Between the Liver and the Spleen by CT</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".09" spread=".10"/>
                    <measurement group_id="O2" value="-0.16" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peripheral Insulin Sensitivity</title>
        <description>Change in the rate of glucose disposal (Rd) during the low dose clamp. During a clamp procedure, insulin is infused at a dose based on body size and a glucose solution is infused and the rate adjusted every 5 minutes based on a blood glucose reading to maintain the blood glucose stable at 90 mg/dl (normal level). Using glucose isotopes and the rate of the glucose infusion, we are then able to calculate how much glucose the liver is producing and how much glucose is being taken up into tissues. This provides a measure of insulin sensitivity.</description>
        <time_frame>0-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peripheral Insulin Sensitivity</title>
          <description>Change in the rate of glucose disposal (Rd) during the low dose clamp. During a clamp procedure, insulin is infused at a dose based on body size and a glucose solution is infused and the rate adjusted every 5 minutes based on a blood glucose reading to maintain the blood glucose stable at 90 mg/dl (normal level). Using glucose isotopes and the rate of the glucose infusion, we are then able to calculate how much glucose the liver is producing and how much glucose is being taken up into tissues. This provides a measure of insulin sensitivity.</description>
          <units>mg/minute/kg lean mass</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.51"/>
                    <measurement group_id="O2" value="-0.42" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Intra-abdominal Fat Area by CT Scan</title>
        <time_frame>0-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intra-abdominal Fat Area by CT Scan</title>
          <units>mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="885" spread="874"/>
                    <measurement group_id="O2" value="108" spread="3416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hepatic Insulin Sensitivity</title>
        <description>Hepatic insulin sensitivity was determined using stable glucose isotope measurements during the low dose hyperinsulinemic euglycemic clamp to determine the rate of endogenous glucose production in the fasting state and in response to a low dose glucose infusion. The ability of insulin to suppress glucose, which is mainly produced by the liver, thus provides a measure of hepatic insulin sensitivity and is expressed as a percentage of the basal state. Change in the ability of low dose insulin to suppress endogenous glucose production during a labeled hyperinsulinemic euglycemic clamp.</description>
        <time_frame>0-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Insulin Sensitivity</title>
          <description>Hepatic insulin sensitivity was determined using stable glucose isotope measurements during the low dose hyperinsulinemic euglycemic clamp to determine the rate of endogenous glucose production in the fasting state and in response to a low dose glucose infusion. The ability of insulin to suppress glucose, which is mainly produced by the liver, thus provides a measure of hepatic insulin sensitivity and is expressed as a percentage of the basal state. Change in the ability of low dose insulin to suppress endogenous glucose production during a labeled hyperinsulinemic euglycemic clamp.</description>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="7.8"/>
                    <measurement group_id="O2" value="4.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline and monthly.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>matching placebo for fenofibrate 1 capsule po qd
matching placebo for pioglitazone 1 capsule po qd</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>micronized fenofibrate 200 mg 1 po qd
matching placebo for pioglitazone 1 po qd</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>pioglitazone 30 mg po qd
matching placebo for fenofibrate 1 po qd</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leg edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>vasovagal reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>gout attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased serum creatinine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to low enrollment, the study was stopped prematurely. Due to the low number of subjects enrolled, statistical analysis was not possible on the intervention study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kristina Utzschneider</name_or_title>
      <organization>VA Puget Sound Health Care System</organization>
      <phone>206-277-3568 ext 6-3568</phone>
      <email>kutzschn@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

